As we found that higher co‐expressions of Gal‐3 and CXCR2 correlated with a significantly worse survival rate, Gal‐3 may be a prognostic biomarker and innovative target for the combined modality therapy of RCC. The gene discussed is CXCR2; the disease is renal cell carcinoma.